<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25145" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Migraine With Aura</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shankar Kikkeri</surname>
            <given-names>Nidhi</given-names>
          </name>
          <aff>Princeton Baptist Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nagalli</surname>
            <given-names>Shivaraj</given-names>
          </name>
          <aff>Yuma Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nidhi Shankar Kikkeri declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shivaraj Nagalli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25145.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Migraine syndrome with aura is a prevalent headache disorder affecting approximately 12% of the general population, with nearly 25% of cases experiencing localized sensory symptoms or auras. Clinical features vary widely, including visual disturbances, speech difficulties, and limb numbness, requiring careful diagnosis. Migraine with aura carries an increased risk of cerebrovascular accidents, prompting timely diagnosis and appropriate treatment.</p>
        <p>This activity&#x000a0;discusses the underlying pathophysiology, and clinicians gain insight into the mechanisms driving migraine attacks, moving beyond outdated theories about cranial blood vessel changes. Moreover, clinicians will learn about evidence-based strategies for managing migraines with aura, including acute treatment and preventative measures. By acquiring this knowledge, healthcare professionals can improve their ability to diagnose, treat, and prevent migraine with aura, ultimately enhancing patient outcomes and reducing healthcare costs.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the distinctive features and symptoms of migraine with aura to facilitate an accurate and prompt diagnosis.</p></list-item><list-item><p>Implement evidence-based diagnostic criteria and guidelines in assessing and diagnosing migraine with aura, ensuring consistency and accuracy in clinical practice.</p></list-item><list-item><p>Select appropriate pharmacological and nonpharmacological interventions based on the individual patient's characteristics, preferences, and the severity of migraine with aura symptoms.</p></list-item><list-item><p>Collaborate with an interdisciplinary healthcare team to facilitate care for patients with migraine with aura, improving overall patient care.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25145&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25145">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25145.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Migraine is a prevalent condition generally characterized by a unilateral pulsating headache developing gradually over hours to days. Approximately 25% of individuals with migraines experience accompanying focal neurological symptoms or auras either before or with the headache. Despite traditional teachings emphasizing the occurrence of auras preceding headaches, many patients experience both simultaneously. Auras manifest as visual, auditory, motor, or somatosensory symptoms.</p>
        <p>Migraine attacks progress through 4 phases: prodrome, aura, headache, and postdrome. Earlier&#x000a0;theories linked the pain of migraine headaches to cranial blood vessel vasodilation and auras to subsequent vasoconstriction. However, current research indicates a genetic foundation along with cortical spreading depression of Le&#x000e3;o as the fundamental cause. Understanding the intricacies of the pathophysiology, presentation, assessment, and management of migraine with aura is crucial for healthcare professionals. Adopting a collaborative team approach enhances the comprehensive care provided to affected individuals.</p>
      </sec>
      <sec id="article-25145.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Current knowledge indicates that primary neuronal dysfunction leads to a sequence of intracranial and extracranial changes that cause migraines. Cortical spreading depression of Le&#x000e3;o, a self-propagating wave of neuronal and glial depolarization that spreads across the cerebral cortex, underlies the etiology of both the headache and aura associated with migraine.<xref ref-type="bibr" rid="article-25145.r1">[1]</xref>&#x000a0;This cortical depression activates trigeminal afferents, causing an inflammatory molecular cascade of events in the meninges, generating the pain associated with migraine.&#x000a0;</p>
        <p>
<bold>Genetics and Inheritance</bold>
</p>
        <p>Migraine&#x000a0;exhibits a strong genetic component. Relatives of patients with migraine have a 3 times higher risk of developing migraine than those&#x000a0;without a familial&#x000a0;history.&#x000a0;However, the precise&#x000a0;genetic&#x000a0;mechanisms involved are&#x000a0;complex and&#x000a0;warrant&#x000a0;comprehensive understanding. Diverse abnormalities related to membrane channels, receptor families, and enzyme systems are observed among affected families. Most likely, multiple genes at multiple genetic loci combine with environmental factors to determine an individual's susceptibility.<xref ref-type="bibr" rid="article-25145.r2">[2]</xref><xref ref-type="bibr" rid="article-25145.r3">[3]</xref>&#x000a0;The&#x000a0;equilibrium&#x000a0;between excitation and inhibition at&#x000a0;different levels of the nervous system&#x000a0;plays a pivotal role in determining whether genetically&#x000a0;predisposed individuals&#x000a0;will develop migraine.&#x000a0;</p>
        <p>Genes with a suspected link to migraine are the&#x000a0;<italic toggle="yes">KCNK18</italic>&#x000a0;gene, which encodes for TRESK, a 2-pore domain potassium channel, and the&#x000a0;<italic toggle="yes">CSNK1D</italic>&#x000a0;gene, which encodes casein kinase I isoform delta. In the future, identifying these genes in individuals with migraines&#x000a0;may enable the&#x000a0;prediction of&#x000a0;targeted prophylactic treatments tailored to their genetic profiles.</p>
        <p>
<bold>Triggers</bold>
</p>
        <p>Nearly 75% of patients report at least 1 trigger for their migraine.<xref ref-type="bibr" rid="article-25145.r4">[4]</xref>&#x000a0;Commonly reported migraine triggers include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>High stress or anxiety</p>
          </list-item>
          <list-item>
            <p>Menstruation</p>
          </list-item>
          <list-item>
            <p>Fasting;</p>
          </list-item>
          <list-item>
            <p>Weather like storm fronts, strong winds, and altitude changes</p>
          </list-item>
          <list-item>
            <p>Too little or too much sleep&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Food items like aged cheese</p>
          </list-item>
          <list-item>
            <p>Nitrates</p>
          </list-item>
          <list-item>
            <p>Obesity</p>
          </list-item>
          <list-item>
            <p>Neck pain</p>
          </list-item>
          <list-item>
            <p>Heat</p>
          </list-item>
          <list-item>
            <p>Sexual activity</p>
          </list-item>
          <list-item>
            <p>Alcohol</p>
          </list-item>
          <list-item>
            <p>Smoke</p>
          </list-item>
          <list-item>
            <p>Exercise</p>
          </list-item>
          <list-item>
            <p>Caffeine intake or withdrawal</p>
          </list-item>
          <list-item>
            <p>Exposure to bright lights, loud noise, or strong odors&#x000a0;<xref ref-type="bibr" rid="article-25145.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>Although patients often report monosodium glutamate (MSG) as a general headache trigger, its role as a migraine trigger remains unverified. Similarly, smoking, odors, chocolate, and tyramine have not been conclusively proven as triggers for migraines or general headaches.&#x000a0;</p>
      </sec>
      <sec id="article-25145.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Migraine affects approximately 12% to 15% of the general population. Women&#x000a0;encounter migraines more frequently than men, with 17% of females and 6% of males experiencing attacks each year.<xref ref-type="bibr" rid="article-25145.r6">[6]</xref>&#x000a0;Migraine&#x000a0;ranks as the fourth or fifth leading cause of emergency room visits, accounting for 3% of all emergency visits annually.<xref ref-type="bibr" rid="article-25145.r7">[7]</xref>&#x000a0;</p>
        <p>Migraine prevalence starts to rise during puberty and continues to increase until the age of 35 to 39, with a decrease later in life, especially after menopause.<xref ref-type="bibr" rid="article-25145.r8">[8]</xref>&#x000a0;Additionally, migraine ranks second only to back pain&#x000a0;in terms of&#x000a0;disability when comparing years of life lived with disability.</p>
      </sec>
      <sec id="article-25145.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of migraine involves the cortical spreading depression of Le&#x000e3;o and activation of the trigeminovascular system.<xref ref-type="bibr" rid="article-25145.r1">[1]</xref></p>
        <p>
<bold>Cortical Spreading Depression</bold>
</p>
        <p>The depolarization of neuronal and glial cells spreads across the cerebral cortex, leading to:</p>
        <list list-type="bullet">
          <list-item>
            <p>Induction of the migraine aura</p>
          </list-item>
          <list-item>
            <p>Activation of trigeminal nerve afferents</p>
          </list-item>
          <list-item>
            <p>Modification of blood-brain barrier permeability through matrix metalloproteinase activation and upregulation</p>
          </list-item>
        </list>
        <p>Activation of the trigeminal nerve's afferent neurons brings about inflammatory changes in the pain-sensitive meninges, contributing to the headache associated with migraine. Specifically, cortical spreading depression prompts the opening of pannexin-1 megachannels, activating caspase-1. This cascade causes the release of proinflammatory mediators, activation of nuclear factor kappa-B in astrocytes, and the transduction of the inflammatory signal to trigeminal nerve fibers around pial vessels.</p>
        <p>
<bold>Trigeminovascular System</bold>
</p>
        <p>The trigeminovascular system originates from the trigeminal ganglion and upper cervical dorsal roots. These sensory neurons project to innervate significant cerebral vessels, the dura mater, and pial vessels. The convergence of these projections at the trigeminal nucleus caudalis explains the distribution of migraine pain, impacting both the anterior and posterior regions of the head and the upper neck.&#x000a0;Stimulation of the trigeminal ganglion by the proinflammatory mediators results in neurogenic inflammation upon releasing substance P, neurokinin A, and calcitonin-gene-related peptide (CGRP). Neurogenic inflammation is an essential contributor to the prolongation and intensification of the pain of migraine.<xref ref-type="bibr" rid="article-25145.r9">[9]</xref></p>
        <p>
<bold>Calcitonin Gene-Related Peptide</bold>
</p>
        <p>CGRP is a neuropeptide expressed in trigeminal ganglia nerves that serves as a potent vasodilator of cerebral and dural vessels and plays an essential role in the pathogenesis of migraine.<xref ref-type="bibr" rid="article-25145.r10">[10]</xref><xref ref-type="bibr" rid="article-25145.r11">[11]</xref>&#x000a0;CGRP mediates pain transmission from the intracranial vessels to the central nervous system and is involved in the vasodilatory component of neurogenic inflammation.<xref ref-type="bibr" rid="article-25145.r12">[12]</xref></p>
        <p>
<bold>Serotonin</bold>
</p>
        <p>Serotonin, released from the brainstem serotonergic nuclei, may play a role in migraine, although the precise nature of this role is subject to debate.<xref ref-type="bibr" rid="article-25145.r13">[13]</xref>&#x000a0;Proposed mechanisms&#x000a0;for serotonin's involvement in migraine include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Direct action upon the cranial vasculature</p>
          </list-item>
          <list-item>
            <p>The role in central pain control pathways&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cerebral cortical projections of brainstem serotonergic nuclei&#x000a0;<xref ref-type="bibr" rid="article-25145.r14">[14]</xref><xref ref-type="bibr" rid="article-25145.r15">[15]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>It is speculated that serotonin levels are low between migraine attacks,&#x000a0;potentially contributing to a deficiency in the serotonin pain inhibitory system. This deficiency may aid in the activation of the trigeminovascular nociceptive pathways, thereby contributing to migraine episodes.&#x000a0;</p>
        <p>
<bold>Sensitization</bold>
</p>
        <p>Sensitization occurs as the neurons become increasingly sensitive to nociceptive and non-nociceptive stimulation.&#x000a0;This phenomenon&#x000a0;occurs in the primary afferent neurons, the second-order neurons in the trigeminal nucleus caudalis, and higher-order neurons in the central nervous system. Sensitization helps explain the throbbing quality of the pain and exacerbation of pain with activities like coughing, bending, sudden head movements, hyperalgesia, and allodynia.</p>
        <p>
<bold>Genetic Basis</bold>
</p>
        <p>The genetic basis of migraines is complex. While mutations in a single gene may cause some migraine disorders, others result from polymorphisms in&#x000a0;multiple genes.<xref ref-type="bibr" rid="article-25145.r16">[16]</xref>&#x000a0;Family studies suggest that mutations in 3&#x000a0;distinct ion channel genes&#x02014;<italic toggle="yes">CACNA1A</italic>,&#x000a0;<italic toggle="yes">SCN1A,</italic>&#x000a0;and&#x000a0;<italic toggle="yes">ATP1A2&#x02014;</italic> could contribute to genetic&#x000a0;predispositions for migraine disorders. Additionally, hemiplegic migraine, a migraine with motor weakness, is believed to be dominantly inherited.<xref ref-type="bibr" rid="article-25145.r17">[17]</xref></p>
        <p>
<bold>Right-to-Left Cardiac Shunt</bold>
</p>
        <p>Right-to-left cardiac shunts,&#x000a0;notably&#x000a0;patent foramen ovale, have been&#x000a0;associated with migraine. Atrial septal defects and pulmonary arteriovenous malformations&#x000a0;seen in hereditary hemorrhagic telangiectasia may also&#x000a0;have a connection, albeit&#x000a0;to a lesser degree.</p>
        <p>Conflicting evidence exists regarding the link between right-to-left shunts and migraine. Some researchers suggest that a genetic predisposition increasing the risk of a PFO may also&#x000a0;elevate&#x000a0;migraine risk. Another hypothesis suggests that vasoactive substances in venous circulation could trigger migraines, gaining access to cranial circulation when a right-to-left shunt is present. Finally, it is proposed that a right-to-left shunt may serve as a pathway for paradoxical embolism and subsequent cerebral ischemia, potentially triggering migraines.</p>
      </sec>
      <sec id="article-25145.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Migraine is a&#x000a0;recurrent disorder characterized by attacks lasting from hours to days. A typical migraine has 4 phases: the prodromal phase, aura, headache, and the postdromal phase.&#x000a0;</p>
        <p>
<bold>Prodromal Phase</bold>
</p>
        <p>The prodromal phase&#x000a0;precedes the onset of headache by&#x000a0;24 to 48 hours in approximately 77% of patients with migraine. Hallmark symptoms of migraine prodrome&#x000a0;include yawning, irritability, euphoria, neck stiffness, and cravings for specific foods.&#x000a0;</p>
        <p>
<bold>Aura&#x000a0;</bold>
</p>
        <p>Nearly 25% of patients with migraine experience aura, which can precede the headache or coincide with it. Auras develop gradually and consist of positive and negative symptoms, typically lasting no more than 60 minutes. Aura symptoms are entirely reversible.<xref ref-type="bibr" rid="article-25145.r2">[2]</xref>&#x000a0;Positive symptoms arise from active discharge from central nervous system neurons, while negative symptoms result from absence or loss of function.&#x000a0;</p>
        <p>Aura symptoms are primarily visual but can be auditory, motor, or somatosensory. Positive symptoms are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Bright lights, lines, and shapes</p>
          </list-item>
          <list-item>
            <p>Tinnitus or music</p>
          </list-item>
          <list-item>
            <p>Paresthesias</p>
          </list-item>
          <list-item>
            <p>Jerky or repetitive movements&#x000a0;<xref ref-type="bibr" rid="article-25145.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>Examples of negative symptoms are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Loss of vision</p>
          </list-item>
          <list-item>
            <p>Hearing loss</p>
          </list-item>
          <list-item>
            <p>Sensory loss</p>
          </list-item>
          <list-item>
            <p>Inability to move parts of the body&#x000a0;<xref ref-type="bibr" rid="article-25145.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>Patients with a migraine equivalent or acephalic migraine develop an aura without a subsequent headache. This variant of migraine presents a unique challenge in diagnosis and management, requiring careful evaluation to differentiate it from other neurological conditions.</p>
        <p>Visual auras classically begin as a small area of vision loss or the appearance of bright lines or shapes in the visual field, known as a scintillating scotoma.&#x000a0;This visual disturbance&#x000a0;then expands to involve a quadrant or hemifield of vision. Upon resolution, the central vision&#x000a0;is restored&#x000a0;first.</p>
        <p>Sensory auras may occur&#x000a0;independently&#x000a0;but typically&#x000a0;follow visual auras within minutes. A typical sensory aura manifests as tingling localized to a limb or one side of the face. Following the paresthesias, localized numbness may persist for up to 60 minutes. Some patients&#x000a0;may experience sensory auras&#x000a0;within the mouth, including the involvement of half of the tongue. The presence of positive visual or sensory symptoms followed by negative symptoms is characteristic of migraine and&#x000a0;aids in&#x000a0;distinguishing migraine from ischemic events.</p>
        <p>Language and motor auras are less frequently observed.&#x000a0;Patients affected by these auras may experience&#x000a0;transient word-finding difficulties, dysphasia, or unilateral limb or facial weakness. The occurrence of unilateral facial or limb weakness in the presence of a migraine is termed hemiplegic migraine.&#x000a0;</p>
        <p>Some patients may develop cutaneous allodynia, where normally non-painful stimuli such as brushing hair, touching the scalp, shaving, or wearing contact lenses may trigger symptoms associated with migraine. Cutaneous allodynia is believed to result from the sensitization of neurons in the trigeminal pathway, contributing to the pain experienced during migraine attacks.</p>
        <p>
<bold>Headache</bold>
</p>
        <p>The headache&#x000a0;phase of migraine typically manifests unilaterally but can be bilateral. The pain is usually described as throbbing or pulsatile and intensifies gradually over several hours. Nausea, vomiting, photophobia, phonophobia, osmophobia, and cutaneous allodynia are all potential features of the headache phase. Patients&#x000a0;often seek relief in&#x000a0;a dark, quiet environment; if left untreated, symptoms can&#x000a0;persist&#x000a0;for hours to days. The headache associated with migraine may resolve during sleep.&#x000a0;&#x000a0;</p>
        <p>
<bold>Postdrome</bold>
</p>
        <p>Postdrome&#x000a0;commences once the spontaneous throbbing subsides. During this phase, patients can&#x000a0;experience transient headaches&#x000a0;triggered by sudden head movements. Individuals&#x000a0;are often left feeling exhausted,&#x000a0;though&#x000a0;some report elation or euphoria.</p>
        <p>Neurological examination typically yields no concerning findings&#x000a0;in most patients with migraine. Some&#x000a0;individuals may&#x000a0;exhibit cranial and cervical muscle tenderness, conjunctival injection, hypertension or hypotension, and bradycardia or tachycardia. The presence of amaurosis, temporal artery tenderness in older patients, meningismus, fever, lethargy, jaw claudication, seizure, and mental status changes should prompt consideration&#x000a0;of underlying pathology beyond migraine.&#x000a0;</p>
        <p>Migraine variants that present with focal neurological deficits include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hemiplegic migraine: Unilateral paralysis or weakness</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Retinal migraine: Visual disturbance, papilledema, and retinal hemorrhages affecting 1 eye</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Migraine with brainstem aura: Vertigo, dizziness, confusion, dysarthria, tingling of the extremities, and incoordination.</p>
          </list-item>
        </list>
        <p>Ophthalmoplegic migraine, now reclassified as neuritis by the International Headache Society, presents&#x000a0;symptoms such as third nerve palsy, ocular muscle paralysis, and ptosis, which may&#x000a0;involve or spare the pupillary response. The underlying etiology is likely a transient idiopathic inflammatory neuritis.</p>
      </sec>
      <sec id="article-25145.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Migraine diagnosis relies on a clinical assessment, necessitating a comprehensive history and physical examination.&#x000a0;Key&#x000a0;historical data include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Patient's demographic information</p>
          </list-item>
          <list-item>
            <p>Onset of headache</p>
          </list-item>
          <list-item>
            <p>Location of pain</p>
          </list-item>
          <list-item>
            <p>Presence of radiating pain</p>
          </list-item>
          <list-item>
            <p>Intensity of the pain</p>
          </list-item>
          <list-item>
            <p>Qualitative characteristics of pain</p>
          </list-item>
          <list-item>
            <p>Duration of pain</p>
          </list-item>
          <list-item>
            <p>Time of day when pain occurs</p>
          </list-item>
          <list-item>
            <p>Evolution of symptoms over time</p>
          </list-item>
          <list-item>
            <p>Frequency of symptoms</p>
          </list-item>
          <list-item>
            <p>Potential triggers</p>
          </list-item>
          <list-item>
            <p>Coexisting symptoms</p>
          </list-item>
          <list-item>
            <p>Relationship between headache and sleep</p>
          </list-item>
          <list-item>
            <p>Factors exacerbating headache severity</p>
          </list-item>
          <list-item>
            <p>Measures alleviating headache</p>
          </list-item>
          <list-item>
            <p>Efficacy and frequency of medication use for symptom relief</p>
          </list-item>
        </list>
        <p>The diagnostic criteria established by the International Classification of Headache Disorders, 3rd edition (ICHD-3) include migraine without aura and migraine with aura. These criteria serve as&#x000a0;standardized guidelines to aid clinicians in accurately diagnosing migraine.</p>
        <p>
<bold>Migraine Without Aura</bold>
</p>
        <p>At least 5 attacks with the following criteria:</p>
        <list list-type="bullet">
          <list-item>
            <p>Headaches that last 4 to 72 hours, either treated or untreated</p>
          </list-item>
          <list-item>
            <p>Headaches with &#x02265;2 of the 4 following characteristics:
<list list-type="bullet"><list-item><p>Unilateral location</p></list-item><list-item><p>Pulsating or throbbing quality</p></list-item><list-item><p>Moderate or severe pain&#x000a0;</p></list-item><list-item><p>Aggravation by routine physical activity</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>The presence of &#x02265;1 of the following:
<list list-type="bullet"><list-item><p>Nausea</p></list-item><list-item><p>Vomiting</p></list-item><list-item><p>Phonophobia</p></list-item><list-item><p>Photophobia</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>No other ICHD-3 diagnosis better explains the patient's symptoms</p>
          </list-item>
        </list>
        <p>
<bold>Migraine With Aura</bold>
</p>
        <p>At least 2 attacks that meet the following criteria:</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x02265;1&#x000a0;fully reversible aura symptoms:
<list list-type="bullet"><list-item><p>Visual</p></list-item><list-item><p>Sensory</p></list-item><list-item><p>Speech</p></list-item><list-item><p>Language</p></list-item><list-item><p>Motor</p></list-item><list-item><p>Brainstem</p></list-item><list-item><p>Retinal&#x000a0;<xref ref-type="bibr" rid="article-25145.r18">[18]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>&#x02265;3 of the following 6 characteristics:
<list list-type="bullet"><list-item><p>1&#x000a0;aura symptom that spreads gradually over &#x02265;5 min</p></list-item><list-item><p>&#x02265;2&#x000a0;aura symptoms occurring in succession</p></list-item><list-item><p>Individual aura symptoms lasting 5 to 60 minutes</p></list-item><list-item><p>&#x02265;1 unilateral aura symptom</p></list-item><list-item><p>&#x02265;1 positive aura symptom</p></list-item><list-item><p>Headache appears within 60 minutes of aura symptoms&#x000a0;<xref ref-type="bibr" rid="article-25145.r18">[18]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>No other ICHD-3 diagnosis better explains the patient's symptoms&#x000a0;<xref ref-type="bibr" rid="article-25145.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>No specific diagnostic test&#x000a0;is available for migraine. The patient's clinical history and physical examination determine the&#x000a0;necessity for testing. Consider ordering a C-reactive protein or erythrocyte sedimentation rate in&#x000a0;older patients with&#x000a0;scalp tenderness.</p>
        <p>Neuroimaging is unnecessary for stable patients who meet the diagnostic criteria for migraine.&#x000a0;However, if neuroimaging is warranted, magnetic resonance imaging (MRI) is the preferred imaging study. Computed tomography (CT) scans are&#x000a0;reserved&#x000a0;for emergencies. Indications for neuroimaging include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Sudden onset of severe headache</p>
          </list-item>
          <list-item>
            <p>New neurological signs or symptoms on examination</p>
          </list-item>
          <list-item>
            <p>Headache not responding to treatment</p>
          </list-item>
          <list-item>
            <p>Headache duration &#x0003e;72 h</p>
          </list-item>
          <list-item>
            <p>New-onset headaches in patients older than 50</p>
          </list-item>
          <list-item>
            <p>A significant change in the frequency, pattern, or severity of headaches</p>
          </list-item>
          <list-item>
            <p>Severe headache pain described as "the worst headache of my life" or a headache that awakens the patient from sleep</p>
          </list-item>
          <list-item>
            <p>New-onset headache in a patient who is immunocompromised</p>
          </list-item>
          <list-item>
            <p>Associated symptoms or signs suggestive of meningitis or stroke&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Posterior location of a headache, which is especially important in children&#x000a0;<xref ref-type="bibr" rid="article-25145.r19">[19]</xref></p>
          </list-item>
        </list>
        <p>Indications for lumbar puncture are:</p>
        <list list-type="bullet">
          <list-item>
            <p>A severe first or the worst headache of a patient's life</p>
          </list-item>
          <list-item>
            <p>Severe, rapid-onset, recurrent headache</p>
          </list-item>
          <list-item>
            <p>Progressive headache</p>
          </list-item>
          <list-item>
            <p>Unresponsive, chronic, intractable headache</p>
          </list-item>
        </list>
        <p>Neuroimaging&#x000a0;is conducted before considering&#x000a0;a lumbar puncture to&#x000a0;assess for&#x000a0;the presence of a mass lesion or elevated intracranial pressure. This precaution helps ensure the safety and appropriate management of the patient.</p>
      </sec>
      <sec id="article-25145.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Alongside&#x000a0;avoiding migraine triggers, maintaining a daily headache diary&#x000a0;can&#x000a0;aid&#x000a0;in tracking progression&#x000a0;and therapy response. Lifestyle&#x000a0;adjustments to control migraine headaches include following routine meal schedules, exercising regularly, and practicing good sleep hygiene. Biofeedback, stress reduction techniques, and cognitive behavioral therapy are helpful adjunctive treatments.&#x000a0;</p>
        <p>Migraine treatment involves abortive and prophylactic therapy. Abortive treatment (see&#x000a0;<bold>Table 1.&#x000a0;</bold>Acute Therapy for Migraine)&#x000a0;aims to stop&#x000a0;the progression of a current headache, while prophylactic therapy (see <bold>Table 2.&#x000a0;</bold>Preventive Therapy for Migraine)&#x000a0;seeks to reduce the frequency or severity of headaches, thereby improving patients' quality of life. Patients should also implement strategies to avoid migraine triggers.&#x000a0;</p>
        <p>
<bold>Abortive Therapy</bold>
</p>
        <p>Place patients in a dark and quiet environment to alleviate discomfort. To abort a migraine, expedient treatment with a&#x000a0;single&#x000a0;large medication dose is crucial. Treatment yields optimal results when administered promptly, ideally within 15 minutes of symptom onset, particularly mild symptoms. Some patients may require parenteral therapy due to migraine-induced gastric stasis.<xref ref-type="bibr" rid="article-25145.r20">[20]</xref><xref ref-type="bibr" rid="article-25145.r21">[21]</xref><xref ref-type="bibr" rid="article-25145.r22">[22]</xref>&#x000a0;Therapy generally follows a stratified approach.</p>
        <p>
<bold>Nonsteroidal anti-inflammatory medications</bold>
</p>
        <p>Nonsteroidal anti-inflammatory (NSAID) medications are&#x000a0;effective&#x000a0;in treating mild to moderate attacks without accompanying nausea or vomiting. If one NSAID&#x000a0;proves ineffective,&#x000a0;an alternative class of medication is typically required. Commonly used NSAIDs include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Ibuprofen 400 mg to 600 mg</p>
          </list-item>
          <list-item>
            <p>Naproxen 275 mg to 825 mg</p>
          </list-item>
          <list-item>
            <p>Diclofenac 65 mg</p>
          </list-item>
          <list-item>
            <p>Aspirin 900mg to 1000 mg&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Acetaminophen 1000 mg&#x000a0;<xref ref-type="bibr" rid="article-25145.r23">[23]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Triptans </bold>
</p>
        <p>Triptans are&#x000a0;5-hydroxytryptamine<sub>1</sub>&#x000a0;( 5-HT<sub>1</sub>) agonists and are recommended as first-line therapy&#x000a0;for patients&#x000a0;experiencing allodynia and&#x000a0;those with moderate to severe pain.&#x000a0;Triptans, with or without naproxen, are suitable&#x000a0;for treating moderate to severe attacks. Combining NSAIDs with a triptan&#x000a0;has shown&#x000a0;greater&#x000a0;efficacy than using either drug class alone.</p>
        <p>Initial therapy may involve prescribing a single tablet containing sumatriptan succinate 85 mg and naproxen sodium 500 mg.<xref ref-type="bibr" rid="article-25145.r24">[24]</xref>&#x000a0;If necessary, triptan doses may be repeated once after 2 hours. However, patients&#x000a0;should avoid using a different triptan within the same 24-hour period, although they may&#x000a0;use a different formulation of the same triptan&#x000a0;for repeat dosing.</p>
        <list list-type="bullet">
          <list-item>
            <p>Sumatriptan:
<list list-type="bullet"><list-item><p>6 to 12 mg subcutaneous injection over 24 hours or,</p></list-item><list-item><p>20 to 40 mg nasal spray over 24 hours or,</p></list-item><list-item><p>22 to 44 mg of nasal powder over 24 hours or,</p></list-item><list-item><p>or 50 to 200 mg orally over 24 hours</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Zolmitriptan:
<list list-type="bullet"><list-item><p>10 mg per 24 hours dosed as 2.5 to 5 mg as a single dose intranasally or 2.5 mg as a single dose orally</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Eletriptan, rizatriptan, almotriptan</p>
          </list-item>
        </list>
        <p>Unlike NSAIDs, patients who do not respond&#x000a0;favorably&#x000a0;to one triptan&#x000a0;may find relief with another, allowing for individualized therapy approaches.&#x000a0;Limiting triptan use to 10 days per month or 3 days a week is recommended to prevent medication overuse headaches. Reduce&#x000a0;the dose of&#x000a0;rizatriptan to 5 mg&#x000a0;for patients concurrently taking propranolol. Additionally, prescribing sumatriptan, zolmitriptan, and rizatriptan should be avoided in patients&#x000a0;using monoamine oxidase inhibitors.&#x000a0;</p>
        <p>Triptans activate the 5-HT<sub>1B</sub>&#x000a0; and 5-HT<sub>1D</sub>&#x000a0; receptors in coronary arteries and cerebral vessels. Contraindications to triptans include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypersensitivity</p>
          </list-item>
          <list-item>
            <p>Ischemic heart disease&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Coronary artery vasospasm</p>
          </list-item>
          <list-item>
            <p>Prinzmetal angina</p>
          </list-item>
          <list-item>
            <p>Angina pectoris</p>
          </list-item>
          <list-item>
            <p>Myocardial Infarction</p>
          </list-item>
          <list-item>
            <p>History of cerebrovascular syndromes</p>
          </list-item>
          <list-item>
            <p>History of hemiplegic or basilar migraine</p>
          </list-item>
          <list-item>
            <p>Peripheral vascular disease&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Uncontrolled hypertension</p>
          </list-item>
          <list-item>
            <p>Use within 24 hours of ergotamine derivatives</p>
          </list-item>
          <list-item>
            <p>Use within 24 hours of another 5-HT<sub>1</sub>&#x000a0;agonist</p>
          </list-item>
          <list-item>
            <p>Concurrent administration or within 2 weeks of discontinuing an MAO type A inhibitors</p>
          </list-item>
          <list-item>
            <p>Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders</p>
          </list-item>
          <list-item>
            <p>Severe hepatic impairment</p>
          </list-item>
          <list-item>
            <p>Pregnancy</p>
          </list-item>
        </list>
        <p>Combining triptans with selective serotonin reuptake inhibitors (SSRIs) or selective serotonin-noradrenaline reuptake inhibitors (SNRIs) poses a risk of serotonin syndrome. Monitoring patients on this combination for signs of serotonin syndrome is essential. Additionally, triptan medications have the potential to lower the seizure threshold.</p>
        <p>
<bold>Ditans</bold>
</p>
        <p>Lasmiditan, a 5-hydroxytryptamine<sub>1F</sub>&#x000a0;receptor agonist, is available in doses&#x000a0;of 50 mg or 100 mg.&#x000a0;The dosage may be increased&#x000a0;to 100 or 200 mg, but patients should not exceed 1 dose in 24 hours.&#x000a0;A significant&#x000a0;adverse&#x000a0;effect of lasmiditan is dizziness. Patients should refrain from engaging in potentially hazardous activities or driving a motor vehicle for at least 8 hours after each dose. Additional adverse effects&#x000a0;include nausea, fatigue, and paresthesia.<xref ref-type="bibr" rid="article-25145.r25">[25]</xref>&#x000a0;Ditans do not&#x000a0;induce vasoconstriction, making them a suitable option for patients with cardiovascular risks.</p>
        <p>
<bold>Antiemetics</bold>
</p>
        <p>Antiemetics&#x000a0;such as metoclopramide, chlorpromazine, and prochlorperazine are&#x000a0;commonly utilized&#x000a0;as adjunctive therapy&#x000a0;alongside NSAIDs or triptans to&#x000a0;alleviate nausea and vomiting, especially in the emergency department. Diphenhydramine may be&#x000a0;administered to prevent dystonic reactions primarily associated with metoclopramide use.</p>
        <p>
<bold>Calcitonin gene-related peptide antagonists</bold>
</p>
        <p>Small molecule antagonists, or gepants, are oral agents proven effective for acute migraine treatment. Though more commonly used as a prophylactic therapy, some formulations are effective for abortive use. Rimegepant, administered as a single 75 mg dose, and ubrogepant are among the available options.&#x000a0;CGRP antagonists are helpful&#x000a0;for patients who do not respond to conventional therapy or those with coronary artery disease.<xref ref-type="bibr" rid="article-25145.r26">[26]</xref>&#x000a0;Rimegepant has approval for both acute and preventative treatment.<xref ref-type="bibr" rid="article-25145.r27">[27]</xref>&#x000a0;Zavegepant&#x000a0;offers an intranasal option.</p>
        <p>Rimegepant use should be avoided in patients with recent cardiovascular or cerebrovascular ischemic events. Nausea, dysgeusia, and drowsiness are the primary adverse effects associated with CGRP antagonists. Dose adjustments may be necessary&#x000a0;for patients with renal and hepatic impairment, while use should be avoided entirely in patients with severe renal or hepatic impairment. The concurrent use of a CGRP antagonist with a triptan or ergotamine within 2 to 4 hours has not been established.</p>
        <p>
<bold>Ergots</bold>
</p>
        <p>Ergots bind to 5-HT<sub>1B/1D</sub>&#x000a0;receptors and&#x000a0;act as vasoconstrictors by inhibiting dural plasma extravasation&#x000a0;following trigeminal ganglion stimulation in rats and may centrally block the trigeminovascular pathway. The oral bioavailability of ergotamine is very poor. Ergots are effective via intravenous (IV), intramuscular (IM), subcutaneous, and intranasal routes. Dihydroergotamine has&#x000a0;demonstrated&#x000a0;efficacy in treating acute migraine attacks and serving as a bridge therapy for medication overuse headaches and status migrainosus. Nevertheless,&#x000a0;further research is required to establish&#x000a0;the full effectiveness of ergotamine.</p>
        <p>Ergotamine is&#x000a0;contraindicated in patients with severe hepatic or renal impairment, hypertension, ischemic heart disease, as well as pregnancy or breastfeeding. Additionally, it should not be used within 24 hours of triptans or ergot-like agents.</p>
        <p>
<bold>Dexamethasone</bold>
</p>
        <p>For patients&#x000a0;experiencing&#x000a0;severe or prolonged migraines, administering 4 mg of intravenous dexamethasone in combination with an abortive medication&#x000a0;can be&#x000a0;beneficial. This combination&#x000a0;therapy helps reduce&#x000a0;the risk of early headache recurrence. However, it does not immediately relieve headaches.<xref ref-type="bibr" rid="article-25145.r28">[28]</xref><xref ref-type="bibr" rid="article-25145.r29">[29]</xref>&#x000a0;Oral corticosteroids are not&#x000a0;effective&#x000a0;for treating acute migraines.</p>
        <p><bold>Peripheral&#x000a0;nerve&#x000a0;blocking</bold>&#x000a0;</p>
        <p>Nerve blocks targeting the occipital nerve, sphenopalatine ganglion, and trigeminal nerve occipital plexus offer an additional treatment option for migraines.<xref ref-type="bibr" rid="article-25145.r30">[30]</xref><xref ref-type="bibr" rid="article-25145.r31">[31]</xref>&#x000a0;Contraindications&#x000a0;include known allergies to local anesthetics, open skull defects, and overlying skin infections. Pregnancy is considered a relative contraindication for this procedure.</p>
        <p>
<bold>Migraine Treatment in the Emergency Setting</bold>
</p>
        <p>The management of patients presenting to an emergency room with severe migraine headaches associated with nausea and vomiting involves:</p>
        <list list-type="bullet">
          <list-item>
            <p>Sumatriptan</p>
          </list-item>
          <list-item>
            <p>Antiemetics and dopamine receptor blockers like metoclopramide, prochlorperazine, or chlorpromazine</p>
          </list-item>
          <list-item>
            <p>Dihydroergotamine with metoclopramide</p>
          </list-item>
          <list-item>
            <p>Ketorolac</p>
          </list-item>
        </list>
        <p>Adding dexamethasone to the treatment regimen for patients receiving the above therapies is recommended to reduce the risk of early headache recurrence. This adjunctive therapy can help improve the overall efficacy of migraine management in the emergency room setting.</p>
        <p>
<bold>Opioids and Barbiturates</bold>
</p>
        <p>The use of opiates and barbiturates for acute migraine treatment should be reserved as a last resort. Opiates are generally less effective than migraine-specific medications, and there is no evidence&#x000a0;supporting&#x000a0;the efficacy of barbiturates,&#x000a0;such as butalbital-containing substances, in acute migraine treatment. Moreover, opioids and barbiturates&#x000a0;are associated with an increased&#x000a0;risk of chronic migraine and medication overuse headaches.</p>
        <p>
<bold>Prophylactic Therapy</bold>
</p>
        <p>
<bold>Indications for prophylactic therapy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Migraine frequency &#x0003e;2 per month</p>
          </list-item>
          <list-item>
            <p>Duration of individual attacks &#x0003e;24 hours</p>
          </list-item>
          <list-item>
            <p>Headaches causing major disruptions in the patient's lifestyle, with significant disability lasting &#x02265;3 days</p>
          </list-item>
          <list-item>
            <p>Failure or overuse of abortive therapy</p>
          </list-item>
          <list-item>
            <p>Symptomatic medications are contraindicated or ineffective</p>
          </list-item>
          <list-item>
            <p>Use of abortive medications &#x0003e;2 times per week</p>
          </list-item>
          <list-item>
            <p>Hemiplegic migraine or rare headache attacks that produce a profound risk of permanent neurologic injury&#x000a0;<xref ref-type="bibr" rid="article-25145.r32">[32]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>Prophylactic medications begin at low doses and are gradually titrated until the patient achieves the desired therapeutic benefit. The choice of preventative medication can take into account any comorbid conditions. Administration of any prophylactic medication will generally result in a 50% reduction in headache frequency.&#x000a0;</p>
        <p>
<bold>Beta-blockers</bold>
</p>
        <p>It is advisable to avoid&#x000a0;initiating beta-blockers&#x000a0;as initial therapy in patients&#x000a0;older than 60 and&#x000a0;those who smoke. When&#x000a0;prescribed&#x000a0;for hypertension, beta-blockers may be associated with a higher&#x000a0;incidence of stroke and other adverse cardiovascular outcomes.&#x000a0;Exercise caution when using&#x000a0;beta-blockers in patients with asthma, erectile dysfunction, bradycardia, and peripheral vascular disease. Commonly&#x000a0;utilized&#x000a0;agents include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Propranolol in 2 divided doses starting at 40 mg/d; dose range is 40 to 240 mg/d</p>
          </list-item>
          <list-item>
            <p>Metoprolol in 2 divided doses starting at 50 mg/d; dose range is 50 to 200 mg/d&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Nadolol starts at 20 mg/d; the dose ranges from 20 to 240 mg once daily</p>
          </list-item>
          <list-item>
            <p>Atenolol starts at 25 mg/d; the dose ranges from 25 to 100 mg once daily</p>
          </list-item>
        </list>
        <p><bold>Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers</bold>&#x000a0;</p>
        <p>Small studies indicate that angiotensin-converting enzyme inhibitors like lisinopril and angiotensin II receptor blockers like candesartan&#x000a0;may reduce the incidence of migraine. However, due to the limited size of these studies, further investigation is required to determine the efficacy of these medications as prophylaxis for migraine.</p>
        <p>
<bold>Antidepressants</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Amitriptyline beginning at 10 mg at bedtime with the range being 20 mg to 100 mg/d</p>
          </list-item>
          <list-item>
            <p>Venlafaxine starting at 37.5 mg once a day with the dose ranging from 75 to 150 mg/d&#x000a0;</p>
          </list-item>
        </list>
        <p>Common adverse effects&#x000a0;associated with amitriptyline, a tricyclic antidepressant,&#x000a0;include dry mouth, constipation, tachycardia, palpitations, orthostatic hypotension, weight gain, blurred vision, and urinary retention. Confusion is a concern in older adults. Tricyclic antidepressants can be&#x000a0;fatal in cases of overdose and should be avoided in patients at increased risk of suicide. Additionally, antidepressants increase the risk of suicidality in children and young adults, necessitating careful monitoring for the emergence of exacerbation of suicidal thoughts or behaviors in patients undergoing antidepressant treatment.&#x000a0;</p>
        <p><bold>Anticonvulsants</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Valproate at doses between&#x000a0;500 to 1500 mg</p>
          </list-item>
          <list-item>
            <p>Topiramate beginning at 25mg/d and increasing by 25 to 50 mg/wk to a maximum dose of 100 mg twice a day</p>
          </list-item>
        </list>
        <p>Paresthesia is the most common adverse effect of topiramate. Doses greater than 100 mg/d may alter the effects of oral contraceptive medications.</p>
        <p>
<bold>Calcium Channel Blockers</bold>
</p>
        <p>Despite their use, conflicting evidence exists regarding the efficacy of calcium channel blockers (CCBs) like verapamil or flunarizine.<xref ref-type="bibr" rid="article-25145.r33">[33]</xref>&#x000a0;Tolerance may develop with CCBs.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Verapamil starts at 120 mg/d and is divided into 3 doses ranging from 120 to 240 mg.&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>Severe left ventricular dysfunction, hypotension, cardiogenic shock, and sick sinus syndrome are all contraindications to the use of CCBs.</p>
        <p>
<bold>Calcitonin gene-related peptide antagonists</bold>
</p>
        <p>CGRP antagonists are reasonable options for patients who are unresponsive to the above options. They are available in parenteral, large molecules monoclonal antibodies&#x000a0;targeting the CGRP receptor and oral small-molecule antagonists.</p>
        <list list-type="bullet">
          <list-item>
            <p>Eptinezumab dosed&#x000a0;100 to 300 mg IV infusion once every 3 months</p>
          </list-item>
          <list-item>
            <p>Fremanezumab dosed 225 mg subcutaneously once monthly or 675 mg once every 3 months</p>
          </list-item>
          <list-item>
            <p>Atogepant 10, 30, or 60 mg orally once daily</p>
          </list-item>
          <list-item>
            <p>Rimegepant 75 mg orally every other day for prevention and 75 mg once daily for acute treatment</p>
          </list-item>
        </list>
        <p>Studies indicate that a trial of 3 to 6 months may be necessary to evaluate the full effect of some preventative medications. Avoid valproate in women of childbearing age and topiramate during pregnancy.&#x000a0;</p>
        <p>
<bold>Additional Treatment Options</bold>
</p>
        <p>Some other treatment agents are mentioned below. However, more trials are needed to authenticate their recommendation.</p>
        <list list-type="bullet">
          <list-item>
            <p>Injection of botulinum neurotoxin A (BoNT-A)
<list list-type="bullet"><list-item><p>Effective in chronic refractory migraines&#x000a0;<xref ref-type="bibr" rid="article-25145.r34">[34]</xref></p></list-item><list-item><p>Not recommended for&#x000a0;preventive treatment of&#x000a0;episodic&#x000a0;migraine&#x000a0;<xref ref-type="bibr" rid="article-25145.r35">[35]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Coenzyme Q10 (CoQ10)&#x000a0;<xref ref-type="bibr" rid="article-25145.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>Riboflavin&#x000a0;<xref ref-type="bibr" rid="article-25145.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p>Magnesium&#x000a0;<xref ref-type="bibr" rid="article-25145.r38">[38]</xref>
<list list-type="bullet"><list-item><p>The usual dose is 400 to 600 mg daily for migraine prevention</p></list-item><list-item><p>Gastrointestinal discomfort and diarrhea are the most common side effects</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Feverfew</p>
          </list-item>
          <list-item>
            <p>Melatonin&#x000a0;<xref ref-type="bibr" rid="article-25145.r39">[39]</xref></p>
          </list-item>
          <list-item>
            <p>Simvastatin plus vitamin D&#x000a0;<xref ref-type="bibr" rid="article-25145.r40">[40]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25145.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses&#x000a0;for migraine include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Tension-type&#x000a0;headache</p>
          </list-item>
          <list-item>
            <p>Cluster headache</p>
          </list-item>
          <list-item>
            <p>Transient ischemic attack (TIA)</p>
          </list-item>
          <list-item>
            <p>Syncope</p>
          </list-item>
          <list-item>
            <p>Vestibular disorders</p>
          </list-item>
          <list-item>
            <p>Headache due to other secondary causes like trauma and intracranial lesions</p>
          </list-item>
          <list-item>
            <p>Cervical artery dissection</p>
          </list-item>
        </list>
        <p>A tension-type headache typically manifests bilaterally, with patients describing a sensation of pressure or tightness around the head that fluctuates over time. Unlike migraine headaches, individuals with&#x000a0;tension-type headaches generally do not present with photophobia, nausea, or vomiting. The pain associated with tension-type headaches is severe and reaches a crescendo within minutes.&#x000a0;Symptoms&#x000a0;observed&#x000a0;in cluster headaches include ipsilateral redness and lacrimation of the eye, rhinorrhea, nasal congestion, sweating, and responsiveness to oxygen therapy.&#x000a0;</p>
        <p>The gradual onset, followed by complete resolution, aids in distinguishing migraine aura from ischemic events such as TIA. Additionally, patients&#x000a0;experiencing&#x000a0;a TIA are less likely to exhibit positive aura symptoms like visual scintillations or paresthesias, along with associated symptoms&#x000a0;such as photophobia, phonophobia, nausea, and vomiting.</p>
      </sec>
      <sec id="article-25145.s10" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <p>&#x000a0;<bold>Table 1. Acute Therapy for Migraine</bold></p>
        <table-wrap id="article-25145.table0" position="float" orientation="portrait">
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<bold>Drug Class/Drug</bold>
</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<bold>Drug</bold>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<bold>Dose Range</bold>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<bold>Notes</bold>
</td>
              </tr>
              <tr style="height: 142px;">
                <td style="width: 236px; height: 142px;" rowspan="1" colspan="1">Nonsteroidal anti-inflammatory drugs&#x000a0;<xref ref-type="bibr" rid="article-25145.r41">[41]</xref></td>
                <td style="width: 236.0625px; height: 142px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Aspirin&#x000a0;<xref ref-type="bibr" rid="article-25145.r23">[23]</xref></p></list-item><list-item><p>Ibuprofen</p></list-item><list-item><p>Naproxen sodium</p></list-item><list-item><p>Diclofenac</p></list-item><list-item><p>Tolfemanic acid</p></list-item><list-item><p>Celecoxib&#x000a0;<xref ref-type="bibr" rid="article-25145.r42">[42]</xref></p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 142px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>325 to 1000 mg every 4 to 6 hours (maximum dose 4000 mg/d)</p></list-item><list-item><p>400 mg every 4 to 6 hours or 600 to 800 mg every 6 to 8 hours</p></list-item><list-item><p>275 to 550 mg every 12 hours&#x000a0;</p></list-item><list-item><p>50 mg every 8 to 12 hours</p></list-item><list-item><p>200 mg may repeat once after 2 hours</p></list-item><list-item><p>200 mg daily or 100 mg every 12 hours</p></list-item></list>
</td>
                <td style="width: 236px; height: 142px;" rowspan="1" colspan="1">All NSAIDs have similar efficacy&#x000a0;</td>
              </tr>
              <tr style="height: 37px;">
                <td style="width: 236px; height: 37px;" rowspan="1" colspan="1">Nonopioid analgesic</td>
                <td style="width: 236.0625px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Acetaminophen&#x000a0;<xref ref-type="bibr" rid="article-25145.r43">[43]</xref></p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>1000 mg every 6 hours</p></list-item></list>
</td>
                <td style="width: 236px; height: 37px;" rowspan="1" colspan="1">Acute-life threatening hepatotoxicity at &#x0003e; 4 g/d</td>
              </tr>
              <tr style="height: 586px;">
                <td style="width: 236px; height: 586px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Sumatriptan)&#x000a0;<xref ref-type="bibr" rid="article-25145.r43">[43]</xref>*</p>
</td>
                <td style="width: 236.0625px; height: 586px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Sumatriptan (oral)</p></list-item></list>
<list list-type="bullet"><list-item><p>Sumatriptan (intranasal solution)</p></list-item></list>
<list list-type="bullet"><list-item><p>Sumatriptan (intranasal powder)</p></list-item></list>
<list list-type="bullet"><list-item><p>Sumatriptan (spray)</p></list-item></list>
<list list-type="bullet"><list-item><p>Sumatriptan (subcutaneous)</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 586px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>50 to 100 mg as a single oral dose</p></list-item><list-item><p>May repeat the dose after 2 hours</p></list-item><list-item><p>maximum dose of 200 mg/d&#x000a0;<xref ref-type="bibr" rid="article-25145.r44">[44]</xref></p></list-item></list>
<list list-type="bullet"><list-item><p>20 mg as a single dose in 1 nostril</p></list-item><list-item><p>May repeat dose after &#x02265;2 hours,</p></list-item><list-item><p>Maximum dose 40 mg/d</p></list-item></list>
<list list-type="bullet"><list-item><p>22 mg as a single dose</p></list-item><list-item><p>May repeat dose after &#x02265;2 hours&#x000a0;</p></list-item><list-item><p>Maximum dose 44 mg/d</p></list-item></list>
<list list-type="bullet"><list-item><p>10 mg as a single dose in 1 nostril</p></list-item><list-item><p>May repeat dose after &#x02265;1 hour&#x000a0; Maximum dose 30 mg/d</p></list-item></list>
<list list-type="bullet"><list-item><p>6 mg as a single subcutaneous dose</p></list-item><list-item><p>May repeat dose&#x000a0; same or smaller dose after &#x02265;1 hour&#x000a0;</p></list-item><list-item><p>Maximum dose 6 mg/dose and 12 mg/d&#x000a0;<xref ref-type="bibr" rid="article-25145.r45">[45]</xref></p></list-item></list>
</td>
                <td style="width: 236px; height: 586px;" rowspan="1" colspan="1">
<p>The unpleasant taste&#x000a0;is lower with intranasal zolmitriptan than with intranasal sumatriptan.</p>
<p>Patients who do not respond to one triptan may respond to another.</p>
<p>Naratriptan and frovatriptan have a slower&#x000a0;onset and lower efficacy.</p>
<p>Subcutaneous is more efficacious than the oral route.</p>
</td>
              </tr>
              <tr style="height: 108px;">
                <td style="width: 236px; height: 108px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Naratriptan)&#x000a0;</p>
</td>
                <td style="width: 236.0625px; height: 108px;" rowspan="1" colspan="1">&#x000a0;
<list list-type="bullet"><list-item><p>Naratriptan&#x000a0;<xref ref-type="bibr" rid="article-25145.r46">[46]</xref></p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 108px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>2.5 mg as a single dose</p></list-item><list-item><p>May repeat dose after &#x02265;4 hours</p></list-item><list-item><p>Maximum dose 2.5 mg/dose and 5 mg/d</p></list-item></list>
</td>
                <td style="width: 236px; height: 108px;" rowspan="1" colspan="1">
<p>Slower onset and longer duration of effect than other triptans.</p>
<p>Likely has lower efficacy but may be better tolerated than other triptans.</p>
<p>Repeat the dose after 4 hours.</p>
<p>Contraindicated with severe renal impairment (CrCl &#x0003c;15 mL/min).</p>
</td>
              </tr>
              <tr style="height: 164px;">
                <td style="width: 236px; height: 164px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Zolmitriptan)&#x000a0;<xref ref-type="bibr" rid="article-25145.r47">[47]</xref></p>
</td>
                <td style="width: 236.0625px; height: 164px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x000a0;Zolmitriptan (oral)</p></list-item></list>
<list list-type="bullet"><list-item><p>Zolmitriptan (intranasal)</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 164px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x000a0;2.5 mg as a single dose</p></list-item><list-item><p>May repeat dose after &#x02265;2 hours</p></list-item><list-item><p>Maximum dose 5 mg/dose and 10 mg/d</p></list-item></list>
<list list-type="bullet"><list-item><p>2.5 to 5 mg as a single intranasal dose</p></list-item><list-item><p>May repeat dose after &#x02265;2 hours</p></list-item><list-item><p>Maximum dose 5 mg/dose and 10 mg/d</p></list-item></list>
</td>
                <td style="width: 236px; height: 164px;" rowspan="1" colspan="1">
<p>The oral tablet but not ODT may be split.</p>
</td>
              </tr>
              <tr style="height: 82px;">
                <td style="width: 236px; height: 82px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Frovatriptan)</p>
</td>
                <td style="width: 236.0625px; height: 82px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Frovatriptan&#x000a0;</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 82px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>2.5 mg as a single dose</p></list-item><list-item><p>May repeat dose after &#x02265;2 hours</p></list-item><list-item><p>Maximum dose 2.5 mg/dose and 5 mg/d &#x000a0;</p></list-item></list>
</td>
                <td style="width: 236px; height: 82px;" rowspan="1" colspan="1">
<p>Slower onset and longer duration of effect than many other triptans.</p>
<p>May have lower efficacy than other triptans but be better tolerated.</p>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Almotriptan)&#x000a0;</p>
</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Almotriptan&#x000a0;</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>12.5 mg as a single dose</p></list-item><list-item><p>May repeat dose after &#x02265;2 hours&#x000a0;</p></list-item><list-item><p>Maximum dose 12.5 mg/dose and 25 mg/d&#x000a0;</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Reduce dose by half in patients with&#x000a0;hepatic impairment.&#x000a0;</p>
<p>Possibly better tolerated than other triptans.</p>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Rizatriptan)</p>
</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Rizatriptan&#x000a0;<xref ref-type="bibr" rid="article-25145.r48">[48]</xref></p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>5 to 10 mg as a single dose</p></list-item><list-item><p>May repeat dose after &#x02265;2 hours&#x000a0;</p></list-item><list-item><p>maximum dose 20-30 mg/d</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Propranolol increases rizatriptan levels by 70%. The dose of rizatriptan&#x000a0;must be adjusted downward in these patients.</p>
<p>10 mg film cannot be split.</p>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Serotonin 1b/1d agonists (triptans)</p>
<p>(Eletriptan)</p>
</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Eletriptan</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>40 mg as a single dose</p></list-item><list-item><p>May repeat dose after &#x02265;2 hours</p></list-item><list-item><p>maximum dose 40 mg/dose and 80 mg/d&#x000a0;<xref ref-type="bibr" rid="article-25145.r49">[49]</xref></p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>40 mg dose is more efficacious, but 20 mg may be better tolerated.</p>
<p>Primarily metabolized by cytochrome P-450 enzyme CYP3A4. Not advised within at least 72 hours of treatment with other&#x000a0;potent CYP3A4 inhibitors like itraconazole, ketoconazole, clarithromycin, nefazodone,&#x000a0;troleandomycin, ritonavir, and nelfinavir.</p>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>&#x000a0;Antiemetics</p>
</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Metoclopramide (IV, IM, oral)&#x000a0;<xref ref-type="bibr" rid="article-25145.r50">[50]</xref></p></list-item></list>
<list list-type="bullet"><list-item><p>Prochlorperazine (IV, IM)</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>10 to 20 mg as a single dose</p></list-item></list>
<list list-type="bullet"><list-item><p>10 mg as a single dose</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">The intravenous route is preferred for metoclopramide. Pretreat with diphenhydramine to prevent akathisia and other acute dystonic reactions.</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">Calcitonin-gene-related peptide antagonists</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Rimegepant&#x000a0;<xref ref-type="bibr" rid="article-25145.r51">[51]</xref></p></list-item></list>
<list list-type="bullet"><list-item><p>Ubrogepant&#x000a0;<xref ref-type="bibr" rid="article-25145.r26">[26]</xref></p></list-item></list>
<list list-type="bullet"><list-item><p>Atogepant&#x000a0;<xref ref-type="bibr" rid="article-25145.r52">[52]</xref><xref ref-type="bibr" rid="article-25145.r53">[53]</xref><xref ref-type="bibr" rid="article-25145.r52">[52]</xref></p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>75 mg every other day</p></list-item><list-item><p>maximum dose 75 mg/d</p></list-item></list>
<list list-type="bullet"><list-item><p>50 to 100 mg as a single dose</p></list-item><list-item><p>may repeat dose after &#x02265;2 hours</p></list-item><list-item><p>maximum dose 200 mg/d</p></list-item></list>
<list list-type="bullet"><list-item><p>10 to 60 mg once daily; maximum dose: 60 mg/d</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Administration early in the course of a migraine attack may improve response to treatment.</p>
<p>Second-line therapy when triptans are contraindicated, poorly tolerated, or ineffective.</p>
<p>Atogepant is avoided in patients with&#x000a0;recent cardiovascular or cerebrovascular ischemic events.&#x000a0;</p>
<p>Use is generally avoided with hepatic impairment, except for ubrogepant, which can be given&#x000a0;50 mg as a single dose.</p>
<p>Renal impairment requires adjustment for all.</p>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">Serotonin 5-HT1F receptor agonist</td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Lasmiditan</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>50 to 100 mg as a single dose</p></list-item><list-item><p>May increase to 100 or 200 mg as a single dose&#x000a0;</p></list-item><list-item><p>Repeat doses have not established efficacy&#x000a0;<xref ref-type="bibr" rid="article-25145.r54">[54]</xref></p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Administration early in the course of a migraine attack may improve response to treatment.</p>
<p>Second-line therapy when triptans are contraindicated, poorly tolerated, or ineffective.</p>
<p>A significant side effect is dizziness (9% to 17%). Wait at least 8 hours between dosing and driving or operating heavy machinery.</p>
<p>Lasmiditan may enhance the CNS depressant effect of alcohol.</p>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">&#x000a0;Ergot derivative&#x000a0;<xref ref-type="bibr" rid="article-25145.r55">[55]</xref></td>
                <td style="width: 236.0625px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x000a0;Dihydroergotamine</p></list-item></list>
</td>
                <td style="width: 234.9375px; height: 15px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>IM:&#x000a0;1 mg as a single dose</p></list-item><list-item><p>May repeat hourly as required</p></list-item><list-item><p>Maximum dose 3 mg/d and 6 mg/wk</p></list-item></list>
<list list-type="bullet"><list-item><p>IV:&#x000a0;1 mg as a single dose</p></list-item><list-item><p>May repeat hourly as required</p></list-item><list-item><p>Maximum dose 2 mg/d and 6 mg/wk</p></list-item></list>
<list list-type="bullet"><list-item><p>Subcutaneous: 1 mg as a single dose</p></list-item><list-item><p>May repeat after 2 hours&#x000a0;</p></list-item><list-item><p>Maximum dose 3 mg/d and 6 mg/wk</p></list-item></list>
<list list-type="bullet"><list-item><p>Intranasal:&#x000a0;0.5 mg per spray: 1 spray into each nostril</p></list-item><list-item><p>Repeat after 15 minutes for a total of 4 sprays per dose</p></list-item><list-item><p>maximum dose 4 sprays/d</p></list-item></list>
</td>
                <td style="width: 236px; height: 15px;" rowspan="1" colspan="1">
<p>Avoid use with potent inhibitors of CYP3A4, including azole antifungals, protease inhibitors, and some macrolide antibiotics.</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>*Adverse effects in this section pertain to all the triptans unless specified</p>
        <table-wrap id="article-25145.table1" position="float" orientation="portrait">
          <caption>
            <title>Table 2. Preventive Therapy for Migraine</title>
          </caption>
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr style="height: 15px;">
                <td style="width: 158px; height: 15px;" rowspan="1" colspan="1">
<bold>Drug Class</bold>
</td>
                <td style="width: 179px; height: 15px;" rowspan="1" colspan="1">
<bold>Drug</bold>
</td>
                <td style="width: 173px; height: 15px;" rowspan="1" colspan="1">
<bold>Dose Range</bold>
</td>
                <td style="width: 217.53125px; height: 15px;" rowspan="1" colspan="1">
<bold>Adverse Effects/Contraindications</bold>
</td>
              </tr>
              <tr style="height: 67px;">
                <td style="width: 158px; height: 67px;" rowspan="1" colspan="1">Beta-adrenoceptor blockers&#x000a0;<xref ref-type="bibr" rid="article-25145.r56">[56]</xref></td>
                <td style="width: 179px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Propranolol</p></list-item><list-item><p>Metoprolol</p></list-item><list-item><p>Timolol</p></list-item></list>
</td>
                <td style="width: 173px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>80 to 240 mg</p></list-item><list-item><p>50 to 150 mg</p></list-item><list-item><p>10 to 20 mg</p></list-item></list>
</td>
                <td style="width: 217.53125px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Contraindicated in asthma, syncope, heart block</p></list-item><list-item><p>Avoid or use with caution in patients with bronchospastic disease, older than 60, depression, fatigue, sexual dysfunction, and tobacco use due to the diminished efficacy of propranolol</p></list-item></list>
</td>
              </tr>
              <tr style="height: 67px;">
                <td style="width: 158px; height: 67px;" rowspan="1" colspan="1">Antidepressants</td>
                <td style="width: 179px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Amitriptyline</p></list-item><list-item><p>Nortriptyline</p></list-item><list-item><p>Venlafaxine</p></list-item></list>
</td>
                <td style="width: 173px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>10 to 150 mg</p></list-item><list-item><p>25 to 100 mg</p></list-item><list-item><p>37.5 to 150 mg</p></list-item></list>
</td>
                <td style="width: 217.53125px; height: 67px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Somnolence</p></list-item><list-item><p>Insomnia, hypertension</p></list-item></list>
</td>
              </tr>
              <tr style="height: 37px;">
                <td style="width: 158px; height: 37px;" rowspan="1" colspan="1">Calcium-channel blockers</td>
                <td style="width: 179px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Verapamil</p></list-item></list>
</td>
                <td style="width: 173px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>180 to 480 mg</p></list-item></list>
</td>
                <td style="width: 217.53125px; height: 37px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Constipation, hypotension, and edema</p></list-item></list>
</td>
              </tr>
              <tr style="height: 97px;">
                <td style="width: 158px; height: 97px;" rowspan="1" colspan="1">Antiepileptic drugs</td>
                <td style="width: 179px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Divalproex sodium</p></list-item><list-item><p>Topiramate</p></list-item><list-item><p>Gabapentin</p></list-item></list>
</td>
                <td style="width: 173px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>200 to 1500 mg</p></list-item><list-item><p>25 to 150 mg</p></list-item><list-item><p>300 to 1800 mg</p></list-item></list>
</td>
                <td style="width: 217.53125px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Weight gain, thrombocytopenia, and&#x000a0; tremor</p></list-item><list-item><p>Renal calculi, amnesia, glaucoma, dysequilibrium, and weight loss</p></list-item></list>
</td>
              </tr>
              <tr style="height: 97px;">
                <td style="width: 158px; height: 97px;" rowspan="1" colspan="1">CGRP monoclonal antibodies</td>
                <td style="width: 179px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Erenumab<xref ref-type="bibr" rid="article-25145.r57">[57]</xref></p></list-item></list>
<list list-type="bullet"><list-item><p>Galcanezumab</p></list-item></list>
<list list-type="bullet"><list-item><p>Fremanezumab&#x000a0;<xref ref-type="bibr" rid="article-25145.r58">[58]</xref></p></list-item></list>
<list list-type="bullet"><list-item><p>Eptinezumab&#x000a0;<xref ref-type="bibr" rid="article-25145.r59">[59]</xref></p></list-item></list>
</td>
                <td style="width: 173px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>70 to 140 mg every 4 weeks, subcutaneously</p></list-item></list>
<list list-type="bullet"><list-item><p>120 mg subcutaneously monthly&#x000a0;</p></list-item></list>
<list list-type="bullet"><list-item><p>225 mg once a month or 675 mg every 3 months administered subcutaneously</p></list-item></list>
<list list-type="bullet"><list-item><p>IV infusion of 100 mg over 30 minutes every 3 months</p></list-item></list>
</td>
                <td style="width: 217.53125px; height: 97px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Injection site reaction, muscle spasms, hypersensitivity reactions</p></list-item><list-item><p>Injection site reactions, vertigo, pruritus, and constipation</p></list-item><list-item><p>Avoid in patients with cardiovascular illness</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-25145.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Though&#x000a0;relatively benign, migraine can significantly affect patients' quality of life. Migraine is a chronic condition that tends to diminish in frequency and severity with age. Menstrual migraine tends to improve after menopause. Incorporating lifestyle changes, including meal schedules and good sleep hygiene, improves overall prognosis.</p>
      </sec>
      <sec id="article-25145.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The complications of migraine include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Status migrainosus:&#x000a0;Status migrainosus is a debilitating migraine attack lasting more than 72 hours. Some patients with status migrainosus require hospitalization due to the&#x000a0;intensity of the pain.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Migrainous infarction or stroke: Migrainous infarction, or stroke associated with migraine, presents a higher risk in patients with migraine accompanied by aura. This condition entails a migraine attack with aura symptoms lasting over an hour, coupled with infarction visible on neuroimaging. Risk factors commonly observed in patients under 45 include patent foramen ovale, female gender, and oral contraceptive use. Any history of migraine is associated with a higher incidence of significant cardiovascular disease. Patients experiencing migraine with aura have a 2.3-fold increased risk of cardiovascular death, while those with migraine without aura exhibit a risk equivalent to the general population. The reported incidence of stroke due to migraine (migrainous stroke) ranges from 0.8 to 3.4 per 100,000 individuals annually.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Persistent aura without infarction:&#x000a0;Aura lasting longer than 1 week after the headache has ended is considered persistent aura without infarction. Symptoms may resemble migrainous infarction, but neuroimaging does not show infarction.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Migraine-aura triggered seizure:&#x000a0;A seizure triggered by migraine with aura, generally occurring within 1 hour.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Psychiatric disorders:<bold>&#x000a0;</bold>Some patients with migraine headaches are at an increased risk of developing&#x000a0;psychiatric disorders such as major depressive disorder, bipolar disorder, or posttraumatic stress disorder.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25145.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Migraines are&#x000a0;a prevalent condition affecting&#x000a0;adults and children, with a higher incidence observed in women than&#x000a0;men.&#x000a0;Typically, the pain associated with a migraine is unilateral and characterized by a throbbing sensation. Many patients will also experience nausea, vomiting, and sensitivity to light and sounds. Approximately 25% of patients with migraine will experience an aura.</p>
        <p>An aura is a symptom that occurs before or during the migraine headache, often manifesting as visual disturbances. Patients may describe&#x000a0;seeing flashes of bright lights, lines, or shapes and some vision loss. Some patients experience numbness and tingling in their face or limbs, while others may have ringing in the ears. The symptoms of an aura generally develop over 5 minutes and resolve within 60 minutes. Some patients experience a prodrome, or periods of yawning, a feeling of depression, irritability, food cravings, constipation, or a stiff neck up to 48 hours before the onset of a migraine.</p>
        <p>Healthcare professionals can diagnose migraines based on the presentation of symptoms and a physical examination without the need for specific diagnostic tests.&#x000a0;However, some patients with concerning symptoms or an unclear diagnosis may undergo additional evaluations, including blood tests and brain&#x000a0;MRI, to exclude other causes of the headache.</p>
        <p>Many patients find that certain factors, such as specific foods, medications, stress, hormonal changes, flashing lights, and alcohol, can trigger their migraines. Keeping a headache diary is a helpful&#x000a0;strategy&#x000a0;for&#x000a0;tracking headaches' frequency and severity and identifying potential triggers. Trigger avoidance is essential in migraine prevention. Additionally, maintaining&#x000a0;a regular sleep schedule, practicing stress reduction techniques, engaging in regular exercise, and&#x000a0;following a balanced diet can help decrease the frequency of migraines.</p>
        <p>Various medications are available&#x000a0;for the&#x000a0;treatment of migraines. Mild symptoms may respond&#x000a0;to over-the-counter therapies like acetaminophen and ibuprofen, while more severe attacks may require prescription medications like triptans. Patients who experience frequent migraines can use preventative medications to reduce the frequency and severity of migraine attacks. It is essential to take medication to treat the migraine as soon as possible for the highest level of effectiveness. Resting or sleeping in a dark, quiet room is helpful.</p>
        <p>Additional treatments are available for&#x000a0;managing any associated symptoms, such as nausea and vomiting. Patients&#x000a0;with migraine with aura&#x000a0;should avoid taking oral contraceptives due to the&#x000a0;increased risk of stroke. It is crucial to refrain from self-medicating for migraines, as excessive use of medication can lead to worsening headaches.</p>
      </sec>
      <sec id="article-25145.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key points to keep in mind about migraine with aura are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Migraines affect approximately 12% of the population, with about 25% of cases experiencing auras.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Auras involve neuronal and glial depolarization, notably cortical spreading depression of Le&#x000e3;o, rather than just cranial blood vessel changes.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Auras can manifest as visual disturbances, speech difficulties, limb numbness, or other sensory symptoms, typically preceding or occurring concurrently with headaches.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Migraines are diagnosed clinically based on symptoms, including unilateral headaches, nausea, photophobia, and phonophobia. Auras may not always precede headaches.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Management includes both abortive and preventive therapies tailored to individual patient needs. Triptans and NSAIDs are common abortive treatments, while beta-blockers and antiepileptic drugs are often used for prevention.</p>
          </list-item>
          <list-item>
            <p>Migraines, especially with aura, are associated with an increased risk of cerebrovascular accidents.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25145.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Migraine is a prevalent chronic condition that can significantly impair quality of life. Early identification and management are crucial to reducing morbidity and enhancing overall patient well-being. Healthcare professionals from various specialties often encounter patients with headaches. While migraine is primarily diagnosed based on clinical assessment, it shares symptoms with ischemic events and other headache types, occasionally leading to seizures or infarctions. Familiarity with the diverse presentations is essential for clinicians to minimize unnecessary investigations and neuroimaging.</p>
        <p>Managing migraine requires a nuanced approach, striking a balance between providing sufficient symptom relief and avoiding medication overuse headaches. Preventative therapies, although beneficial, may pose challenges due to adverse effects, and intolerance may occur before reaching a therapeutic dose. Successful navigation of these challenges necessitates effective interprofessional and patient-clinician communication to ensure optimal treatment.</p>
        <p>Proper management often leads to a favorable prognosis for most patients with migraine headaches. Nurses, advanced practitioners, and physicians play vital roles in collaborating with patients on lifestyle adjustments and medication education. Pharmacists also contribute significantly by reviewing prescriptions, consulting prescribers on optimal agent selection, assessing drug interactions, and educating patients on usage and side effects.</p>
        <p>Nurses actively monitor and reinforce medication teaching points, serving as a pivotal communication link between clinicians and other team members. To ensure comprehensive patient care, all team members must provide excellent documentation and timely correspondence to facilitate seamless information exchange and collaborative decision-making among the healthcare team. These interprofessional efforts collectively contribute to improved outcomes for patients dealing with migraine headaches.</p>
      </sec>
      <sec id="article-25145.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25145&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25145">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/migraine-headaches/migraine-with-aura/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25145">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25145/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25145">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25145.s17">
        <title>References</title>
        <ref id="article-25145.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fraser</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Hepschke</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Migraine Aura: Pathophysiology, Mimics, and Treatment Options.</article-title>
            <source>Semin Neurol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>739</fpage>
            <page-range>739-748</page-range>
            <pub-id pub-id-type="pmid">31847045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <article-title>Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.</article-title>
            <source>Cephalalgia</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-211</page-range>
            <pub-id pub-id-type="pmid">29368949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merikangas</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Risch</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Merikangas</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Weissman</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Kidd</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Migraine and depression: association and familial transmission.</article-title>
            <source>J Psychiatr Res</source>
            <year>1988</year>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>119</fpage>
            <page-range>119-29</page-range>
            <pub-id pub-id-type="pmid">3404480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelman</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The triggers or precipitants of the acute migraine attack.</article-title>
            <source>Cephalalgia</source>
            <year>2007</year>
            <month>May</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>394</fpage>
            <page-range>394-402</page-range>
            <pub-id pub-id-type="pmid">17403039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marmura</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Triggers, Protectors, and Predictors in Episodic Migraine.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2018</year>
            <month>Oct</month>
            <day>05</day>
            <volume>22</volume>
            <issue>12</issue>
            <fpage>81</fpage>
            <pub-id pub-id-type="pmid">30291562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vetvik</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>MacGregor</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Sex differences in the epidemiology, clinical features, and pathophysiology of migraine.</article-title>
            <source>Lancet Neurol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>76</fpage>
            <page-range>76-87</page-range>
            <pub-id pub-id-type="pmid">27836433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jen</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Dudding</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Baloh</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>No mutations in CACNA1A and ATP1A2 in probands with common types of migraine.</article-title>
            <source>Arch Neurol</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>61</volume>
            <issue>6</issue>
            <fpage>926</fpage>
            <page-range>926-8</page-range>
            <pub-id pub-id-type="pmid">15210532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ebrahimi-Fakhari</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Saffari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Westenberger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The evolving spectrum of PRRT2-associated paroxysmal diseases.</article-title>
            <source>Brain</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>138</volume>
            <issue>Pt 12</issue>
            <fpage>3476</fpage>
            <page-range>3476-95</page-range>
            <pub-id pub-id-type="pmid">26598493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iyengar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Ossipov</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Aurora</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>CGRP and the Trigeminal System in Migraine.</article-title>
            <source>Headache</source>
            <year>2019</year>
            <month>May</month>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>659</fpage>
            <page-range>659-681</page-range>
            <pub-id pub-id-type="pmid">30982963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Correnti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kamm</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kelderman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Papetti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rubio-Beltr&#x000e1;n</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vigneri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Edvinsson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Maassen Van Den Brink</surname>
                <given-names>A</given-names>
              </name>
              <collab>European Headache Federation School of Advanced Studies (EHF-SAS)</collab>
            </person-group>
            <article-title>Blocking CGRP in migraine patients - a review of pros and cons.</article-title>
            <source>J Headache Pain</source>
            <year>2017</year>
            <month>Sep</month>
            <day>25</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>96</fpage>
            <pub-id pub-id-type="pmid">28948500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lauritsen</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Kaiser</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>CGRP Monoclonal Antibodies for Migraine: Rationale and Progress.</article-title>
            <source>BioDrugs</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>487</fpage>
            <page-range>487-501</page-range>
            <pub-id pub-id-type="pmid">29116598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Charles</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pozo-Rosich</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Targeting calcitonin gene-related peptide: a new era in migraine therapy.</article-title>
            <source>Lancet</source>
            <year>2019</year>
            <month>Nov</month>
            <day>09</day>
            <volume>394</volume>
            <issue>10210</issue>
            <fpage>1765</fpage>
            <page-range>1765-1774</page-range>
            <pub-id pub-id-type="pmid">31668411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Hougaard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Knudsen</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Ashina</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Serotonergic mechanisms in the migraine brain - a systematic review.</article-title>
            <source>Cephalalgia</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>251</fpage>
            <page-range>251-264</page-range>
            <pub-id pub-id-type="pmid">27013238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suzuki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Paesschen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Stalmans</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Horita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bergmans</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Legius</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Riant</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>De Jonghe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sekine</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Igarashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mikoshiba</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shimadzu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shiohara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Braverman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Al-Gazali</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Seki</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Defective membrane expression of the Na(+)-HCO(3)(-) cotransporter NBCe1 is associated with familial migraine.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2010</year>
            <month>Sep</month>
            <day>07</day>
            <volume>107</volume>
            <issue>36</issue>
            <fpage>15963</fpage>
            <page-range>15963-8</page-range>
            <pub-id pub-id-type="pmid">20798035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Eom</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YM</given-names>
              </name>
            </person-group>
            <article-title>Epilepsy Characteristics and Clinical Outcome in Patients With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS).</article-title>
            <source>Pediatr Neurol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>64</volume>
            <fpage>59</fpage>
            <page-range>59-65</page-range>
            <pub-id pub-id-type="pmid">27671241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gasparini</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>LR</given-names>
              </name>
            </person-group>
            <article-title>Genetic and biochemical changes of the serotonergic system in migraine pathobiology.</article-title>
            <source>J Headache Pain</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <pub-id pub-id-type="pmid">28194570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sutherland</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>LR</given-names>
              </name>
            </person-group>
            <article-title>Genetics of Migraine: Insights into the Molecular Basis of Migraine Disorders.</article-title>
            <source>Headache</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>57</volume>
            <issue>4</issue>
            <fpage>537</fpage>
            <page-range>537-569</page-range>
            <pub-id pub-id-type="pmid">28271496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tronvik</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Do</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Zecca</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hougaard</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical features of visual migraine aura: a systematic review.</article-title>
            <source>J Headache Pain</source>
            <year>2019</year>
            <month>May</month>
            <day>30</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>64</fpage>
            <pub-id pub-id-type="pmid">31146673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evans</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Burch</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Frishberg</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Marmura</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Mechtler</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Neuroimaging for Migraine: The American Headache Society Systematic Review and Evidence-Based Guideline.</article-title>
            <source>Headache</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>318</fpage>
            <page-range>318-336</page-range>
            <pub-id pub-id-type="pmid">31891197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsu</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Taiwan Headache Society</surname>
                <given-names>TGSOTHS</given-names>
              </name>
            </person-group>
            <article-title>Medical Treatment Guidelines for Acute Migraine Attacks.</article-title>
            <source>Acta Neurol Taiwan</source>
            <year>2017</year>
            <month>Jun</month>
            <day>15</day>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>78</fpage>
            <page-range>78-96</page-range>
            <pub-id pub-id-type="pmid">29250761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cameron</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kotb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Coyle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Skidmore</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gomes</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.</article-title>
            <source>Headache</source>
            <year>2015</year>
            <season>Jul-Aug</season>
            <volume>55 Suppl 4</volume>
            <fpage>221</fpage>
            <page-range>221-35</page-range>
            <pub-id pub-id-type="pmid">26178694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Becker</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Acute Migraine Treatment in Adults.</article-title>
            <source>Headache</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>778</fpage>
            <page-range>778-93</page-range>
            <pub-id pub-id-type="pmid">25877672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biglione</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gitin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gorelick</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Hennekens</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Aspirin in the Treatment and Prevention of Migraine Headaches: Possible Additional Clinical Options for Primary Healthcare Providers.</article-title>
            <source>Am J Med</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>133</volume>
            <issue>4</issue>
            <fpage>412</fpage>
            <page-range>412-416</page-range>
            <pub-id pub-id-type="pmid">31712099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brandes</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kudrow</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stark</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>O'Carroll</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Adelman</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Spruill</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Lener</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.</article-title>
            <source>JAMA</source>
            <year>2007</year>
            <month>Apr</month>
            <day>04</day>
            <volume>297</volume>
            <issue>13</issue>
            <fpage>1443</fpage>
            <page-range>1443-54</page-range>
            <pub-id pub-id-type="pmid">17405970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuca</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Wietecha</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Dozier</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <collab>COL MIG-301 Study Group</collab>
            </person-group>
            <article-title>Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study.</article-title>
            <source>Neurology</source>
            <year>2018</year>
            <month>Dec</month>
            <day>11</day>
            <volume>91</volume>
            <issue>24</issue>
            <fpage>e2222</fpage>
            <page-range>e2222-e2232</page-range>
            <pub-id pub-id-type="pmid">30446595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Ailani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Finnegan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trugman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Szegedi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ubrogepant for the Treatment of Migraine.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Dec</month>
            <day>05</day>
            <volume>381</volume>
            <issue>23</issue>
            <fpage>2230</fpage>
            <page-range>2230-2241</page-range>
            <pub-id pub-id-type="pmid">31800988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blair</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Correction to: Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine.</article-title>
            <source>CNS Drugs</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>37</volume>
            <issue>7</issue>
            <fpage>661</fpage>
            <pub-id pub-id-type="pmid">37402082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giamberardino</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Affaitati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Costantini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guglielmetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martelletti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Acute headache management in emergency department. A narrative review.</article-title>
            <source>Intern Emerg Med</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>109</fpage>
            <page-range>109-117</page-range>
            <pub-id pub-id-type="pmid">31893348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirbaha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Delavar-Kasmaei</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Erfan</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of the Concurrent Intravenous Injection of Dexamethasone and Metoclopramide for Pain Management in Patients with Primary Headaches Presenting to Emergency Department.</article-title>
            <source>Adv J Emerg Med</source>
            <year>2017</year>
            <season>Fall</season>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>e6</fpage>
            <pub-id pub-id-type="pmid">31172058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korucu</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Dagar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>&#x000c7;orbacioglu</surname>
                <given-names>&#x0015e;K</given-names>
              </name>
              <name>
                <surname>Emektar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cevik</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The effectiveness of greater occipital nerve blockade in treating acute migraine-related headaches in emergency departments.</article-title>
            <source>Acta Neurol Scand</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>138</volume>
            <issue>3</issue>
            <fpage>212</fpage>
            <page-range>212-218</page-range>
            <pub-id pub-id-type="pmid">29744871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crespi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bratbak</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Matharu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jamt&#x000f8;y</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Tronvik</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Pilot Study of Injection of OnabotulinumtoxinA Toward the Sphenopalatine Ganglion for the Treatment of Classical Trigeminal Neuralgia.</article-title>
            <source>Headache</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>59</volume>
            <issue>8</issue>
            <fpage>1229</fpage>
            <page-range>1229-1239</page-range>
            <pub-id pub-id-type="pmid">31342515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Freitag</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Argoff</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ashman</surname>
                <given-names>E</given-names>
              </name>
              <collab>Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society</collab>
            </person-group>
            <article-title>Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.</article-title>
            <source>Neurology</source>
            <year>2012</year>
            <month>Apr</month>
            <day>24</day>
            <volume>78</volume>
            <issue>17</issue>
            <fpage>1337</fpage>
            <page-range>1337-45</page-range>
            <pub-id pub-id-type="pmid">22529202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahriman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Migraine and Tension-Type Headache.</article-title>
            <source>Semin Neurol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>608</fpage>
            <page-range>608-618</page-range>
            <pub-id pub-id-type="pmid">30522135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruscheweyh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>F&#x000f6;rderreuther</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gaul</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gendolla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Holle-Lee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>J&#x000fc;rgens</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Neeb</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Straube</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Treatment of chronic migraine with botulinum neurotoxin&#x000a0;A : Expert recommendations of the German Migraine and Headache Society].</article-title>
            <source>Nervenarzt</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>89</volume>
            <issue>12</issue>
            <fpage>1355</fpage>
            <page-range>1355-1364</page-range>
            <pub-id pub-id-type="pmid">29947936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naumann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Argoff</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Childers</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Dykstra</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Gronseth</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Jabbari</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaufmann</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Schurch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>DM</given-names>
              </name>
              <collab>Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology</collab>
            </person-group>
            <article-title>Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.</article-title>
            <source>Neurology</source>
            <year>2008</year>
            <month>May</month>
            <day>06</day>
            <volume>70</volume>
            <issue>19</issue>
            <fpage>1707</fpage>
            <page-range>1707-14</page-range>
            <pub-id pub-id-type="pmid">18458231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000e1;ndor</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Di Clemente</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Coppola</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Saenger</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Fumal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Magis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Seidel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Agosti</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Schoenen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial.</article-title>
            <source>Neurology</source>
            <year>2005</year>
            <month>Feb</month>
            <day>22</day>
            <volume>64</volume>
            <issue>4</issue>
            <fpage>713</fpage>
            <page-range>713-5</page-range>
            <pub-id pub-id-type="pmid">15728298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markley</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>CoEnzyme Q10 and riboflavin: the mitochondrial connection.</article-title>
            <source>Headache</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>52 Suppl 2</volume>
            <fpage>81</fpage>
            <page-range>81-7</page-range>
            <pub-id pub-id-type="pmid">23030537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teigen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Boes</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>An evidence-based review of oral magnesium supplementation in the preventive treatment of migraine.</article-title>
            <source>Cephalalgia</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>10</issue>
            <fpage>912</fpage>
            <page-range>912-22</page-range>
            <pub-id pub-id-type="pmid">25533715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gon&#x000e7;alves</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Martini Ferreira</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ribeiro</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Zukerman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cipolla-Neto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Peres</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Randomised clinical trial comparing melatonin 3&#x02005;mg, amitriptyline 25&#x02005;mg and placebo for migraine prevention.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>87</volume>
            <issue>10</issue>
            <fpage>1127</fpage>
            <page-range>1127-32</page-range>
            <pub-id pub-id-type="pmid">27165014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buettner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nir</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Bertisch</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schain</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mittleman</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Burstein</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial.</article-title>
            <source>Ann Neurol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>78</volume>
            <issue>6</issue>
            <fpage>970</fpage>
            <page-range>970-81</page-range>
            <pub-id pub-id-type="pmid">26418341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zobdeh</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Eremenko</surname>
                <given-names>II</given-names>
              </name>
              <name>
                <surname>Akan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Tarasov</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Chubarev</surname>
                <given-names>VN</given-names>
              </name>
              <name>
                <surname>Schi&#x000f6;th</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Mwinyi</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pharmacogenetics and Pain Treatment with a Focus on Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Antidepressants: A Systematic Review.</article-title>
            <source>Pharmaceutics</source>
            <year>2022</year>
            <month>Jun</month>
            <day>01</day>
            <volume>14</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">35745763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Munjal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brand-Schieber</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study.</article-title>
            <source>Headache</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>58</fpage>
            <page-range>58-70</page-range>
            <pub-id pub-id-type="pmid">31647577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marmura</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Schwedt</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies.</article-title>
            <source>Headache</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-20</page-range>
            <pub-id pub-id-type="pmid">25600718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Derry</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Derry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>May</month>
            <day>28</day>
            <volume>2014</volume>
            <issue>5</issue>
            <fpage>CD009108</fpage>
            <pub-id pub-id-type="pmid">24865446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cady</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Munjal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cady</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Manley</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Brand-Schieber</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Randomized, double-blind, crossover study comparing DFN-11 injection (3&#x000a0;mg subcutaneous sumatriptan) with 6&#x000a0;mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine.</article-title>
            <source>J Headache Pain</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <pub-id pub-id-type="pmid">28176235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Havanka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dahl&#x000f6;f</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pop</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Winter</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Whitehouse</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hassani</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group.</article-title>
            <source>Clin Ther</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>8</issue>
            <fpage>970</fpage>
            <page-range>970-80</page-range>
            <pub-id pub-id-type="pmid">10972633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bird</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Derry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Zolmitriptan for acute migraine attacks in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>May</month>
            <day>21</day>
            <volume>2014</volume>
            <issue>5</issue>
            <fpage>CD008616</fpage>
            <pub-id pub-id-type="pmid">24848613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oldman</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>McQuay</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological treatments for acute migraine: quantitative systematic review.</article-title>
            <source>Pain</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>97</volume>
            <issue>3</issue>
            <fpage>247</fpage>
            <page-range>247-257</page-range>
            <pub-id pub-id-type="pmid">12044621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <article-title>Eletriptan (relpax) for migraine.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2003</year>
            <month>Apr</month>
            <day>28</day>
            <volume>45</volume>
            <issue>1155</issue>
            <fpage>33</fpage>
            <page-range>33-4</page-range>
            <pub-id pub-id-type="pmid">12719695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelley</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others.</article-title>
            <source>Headache</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>52</volume>
            <issue>2</issue>
            <fpage>292</fpage>
            <page-range>292-306</page-range>
            <pub-id pub-id-type="pmid">22309235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Croop</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stock</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Stock</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dubowchik</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Conway</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Coric</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Jul</month>
            <day>11</day>
            <volume>381</volume>
            <issue>2</issue>
            <fpage>142</fpage>
            <page-range>142-149</page-range>
            <pub-id pub-id-type="pmid">31291516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Ailani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Trugman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Finnegan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Szegedi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.</article-title>
            <source>Lancet Neurol</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>9</issue>
            <fpage>727</fpage>
            <page-range>727-737</page-range>
            <pub-id pub-id-type="pmid">32822633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Pozo-Rosich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Blumenfeld</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>McAllister</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dabruzzo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Miceli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Severt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Finnegan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trugman</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.</article-title>
            <source>JAMA Netw Open</source>
            <year>2022</year>
            <month>Jun</month>
            <day>01</day>
            <volume>5</volume>
            <issue>6</issue>
            <fpage>e2215499</fpage>
            <pub-id pub-id-type="pmid">35675076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>VanderPluym</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Halker Singh</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Urtecho</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Nayfeh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Torres Roldan</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Farah</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Hasan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Saadi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abd-Rabu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Daraz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Prokop</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis.</article-title>
            <source>JAMA</source>
            <year>2021</year>
            <month>Jun</month>
            <day>15</day>
            <volume>325</volume>
            <issue>23</issue>
            <fpage>2357</fpage>
            <page-range>2357-2369</page-range>
            <pub-id pub-id-type="pmid">34128998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Capobianco</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Cheshire</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>An overview of the diagnosis and pharmacologic treatment of migraine.</article-title>
            <source>Mayo Clin Proc</source>
            <year>1996</year>
            <month>Nov</month>
            <volume>71</volume>
            <issue>11</issue>
            <fpage>1055</fpage>
            <page-range>1055-66</page-range>
            <pub-id pub-id-type="pmid">8917290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ikeda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Aoyagi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hanashiro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sawada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kyuzen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morioka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ebina</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nagasawa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yanagihashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ishikawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takazawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawabe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iwasaki</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Preventive Treatment with Lomerizine Increases Cerebral Blood Flows during the Interictal Phase of Migraine.</article-title>
            <source>J Stroke Cerebrovasc Dis</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>998</fpage>
            <page-range>998-1002</page-range>
            <pub-id pub-id-type="pmid">29221971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ashina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Xue</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Paiva da Silva Lima</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials.</article-title>
            <source>JAMA Neurol</source>
            <year>2022</year>
            <month>Feb</month>
            <day>01</day>
            <volume>79</volume>
            <issue>2</issue>
            <fpage>159</fpage>
            <page-range>159-168</page-range>
            <pub-id pub-id-type="pmid">34928306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrari</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Ning</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Galic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Grozinski-Wolff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Janka</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ashina</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.</article-title>
            <source>Lancet</source>
            <year>2019</year>
            <month>Sep</month>
            <day>21</day>
            <volume>394</volume>
            <issue>10203</issue>
            <fpage>1030</fpage>
            <page-range>1030-1040</page-range>
            <pub-id pub-id-type="pmid">31427046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25145.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ashina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lanteri-Minet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pozo-Rosich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ettrup</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Christoffersen</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Josiassen</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Phul</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.</article-title>
            <source>Lancet Neurol</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>21</volume>
            <issue>7</issue>
            <fpage>597</fpage>
            <page-range>597-607</page-range>
            <pub-id pub-id-type="pmid">35716692</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
